Initiation of Prophylactic Treatment with Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) for Prevention of Hereditary Angioedema (HAE) Attacks and Onset of Effect: Findings from the Phase III COMPACT Study

Subcutaneous C1-INH (HAEGARDA？, CSL Behring, Marburg) at 60 IU/kg was recently approved by the US FDA as routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescents and adults, based on the COMPACT study. This study demonstrated that the median attack rate was reduced by 95% with C1-INH relative to placebo. We explored the onset of the preventive effect of C1-INH (SC) after treatment initiation.